In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
Commentary|Articles|October 31, 2026
Lonardi on Overall Survival With Nivolumab/Ipilimumab in MSI-H/dMMR mCRC
Author(s)Sara Lonardi, MD, Sabrina Serani
Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
Advertisement
Advertisement
At the 2026 European Society for Medical Oncology (ESMO) Congress, Sara Lonardi, MD, presented the final overall survival (OS) analysis of the phase 3 CheckMate-8HW trial (NCT04008030), which evaluated nivolumab (Opdivo) plus ipilimumab (Yervoy) vs nivolumab monotherapy or chemotherapy in patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC).1,2
Related to this article
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
The GOBLET trial showed durability in patients with previously treated squamous cell anal carcinoma.
ESMO 2026 unveils GI cancer advances: targeted and immunotherapy regimens boost survival in pancreatic, colorectal, gastric, and HER2+ gastroesophageal disease.
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in metastatic castration-resistant prostate cancer.
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.
Advertisement
Advertisement